BioCardia, Inc.
BioCardia, Inc.（BCDA）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · BCDA · 截至 2025年9月30日
股东结构概览
18
机构持有人数
▲ 2 vs Q2
$551,879
机构持仓总市值
▼ $41,328 vs Q2
5.80M
总流通股
freeFloat 71.68%
427,093
13F 申报持股数
▲ 122,749 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
BCDA 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
CM MANAGEMENT, LLC biological products, (no diagnostic substances) | 130.0K | 2.07% | 2.07% | $167.70M | Nov 13, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 96.5K | 1.54% | 1.54% | $124.48M | Nov 7, 2025 | ▲ 83.6K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 38.8K | 61.82% | 61.82% | $50.06M | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 38.7K | 61.71% | 61.71% | $49.97M | Nov 12, 2025 | ▲ 1.3K |
BROWN ADVISORY INC biological products, (no diagnostic substances) | 35.5K | 56.61% | 56.61% | $45.84M | Nov 14, 2025 | — held |
TWO SIGMA SECURITIES, LLC biological products, (no diagnostic substances) | 19.3K | 30.80% | 30.80% | $24.95M | Nov 14, 2025 | NEW |
COMMONWEALTH EQUITY SERVICES, LLC biological products, (no diagnostic substances) | 18.3K | 29.12% | 29.12% | $24.00M | Oct 22, 2025 | ▲ 200 |
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC biological products, (no diagnostic substances) | 17.0K | 27.08% | 27.08% | $22.44M | Oct 29, 2025 | NEW |
XTX TOPCO LTD biological products, (no diagnostic substances) | 16.2K | 25.77% | 25.77% | $20.87M | Nov 14, 2025 | NEW |
UBS GROUP AG biological products, (no diagnostic substances) | 10.7K | 17.11% | 17.11% | $13.85M | Nov 13, 2025 | ▲ 6.6K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
5
增持
+91.7K 股5
新建仓
首次建仓1
减持
−1 股3
清仓
完全退出净股数变化（前50家）
+91.7K
+91.7K / −1
净新增持仓人
+6
新建 5 个 / 退出 3 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
BCDA 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
7
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Altman Peter President and CEO | May 20, 2026 | Purchase | 1,500 | $0.92 | $1.4K | 293.3K | Form 4 ↗ |
Altman Peter President and CEO | May 19, 2026 | Purchase | 200 | $0.95 | $190 | 291.8K | Form 4 ↗ |
Altman Peter President and CEO | May 18, 2026 | Purchase | 5,700 | $0.92 | $5.2K | 291.6K | Form 4 ↗ |
Altman Peter President and CEO | May 15, 2026 | Purchase | 5,100 | $1.02 | $5.2K | 285.9K | Form 4 ↗ |
Altman Peter President and CEO | Apr 29, 2026 | Purchase | 5,000 | $1.11 | $5.6K | 280.8K | Form 4 ↗ |
Altman Peter President and CEO | Apr 21, 2026 | Purchase | 400 | $1.23 | $492 | 275.8K | Form 4 ↗ |
Altman Peter President and CEO | Apr 20, 2026 | Purchase | 600 | $1.23 | $738 | 275.4K | Form 4 ↗ |
Altman Peter President and CEO | Mar 25, 2026 | Purchase | 300 | $1.22 | $366 | 274.8K | Form 4 ↗ |
Altman Peter President and CEO | Mar 24, 2026 | Purchase | 600 | $1.24 | $744 | 274.5K | Form 4 ↗ |
Altman Peter President and CEO | Feb 4, 2026 | Purchase | 5,000 | $1.13 | $5.6K | 273.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
BioCardia, Inc.（BCDA）主要由机构投资者持有，机构持股比例约为 7.4%。公司内部人员持股约 28.32%，散户及公众持股约占剩余的 64.32%。
BioCardia, Inc. 最大机构股东为 CM MANAGEMENT, LLC，截至 September 30, 2025 持有约 130,000 股，占总流通股的 2.07%。
目前共有 18 家机构持有 BCDA 股票，合计持仓市值约 $551,879，数据来源为最新 SEC 13F 申报。
常见问题
BCDA ownershipBioCardia, Inc.（BCDA）主要由机构投资者持有，机构持股约 7.4%。最大股东为 CM MANAGEMENT, LLC，持股比例 2.07%。内部人员持股约 28.32%。数据来源 SEC Form 13F，截至 September 30, 2025。